A new interventional neurovascular coil offers better results for treating cerebral aneurysms than its platinum-based counterparts, according to new research.

MicroVention's HydroCoil Embolic System features a non-bioactive coil which links greater aneurysm volume filling features with biologically inert scaffolding for natural tissue proliferation.

The company ran an 18-month test on 500 patients and found that the HydroCoil, which is based on a microporous expandable hydrogel, surpassed bare platinum as a durable solution for endovascular occlusion of aneurysms.

Angiographic data revealed that the new design offered a statistically significant 8.6 per cent less aneurysm recurrence than had previously been provided by alternative treatments.

"These are outstanding results on the safety and effectiveness of HydroCoil and confirm our belief that HydroCoil is the optimal device for treating a broad spectrum of cerebral aneurysms as compared to bare platinum coils," said Richard Cappetta, President and Chief Executive of MicroVention-Terumo.

"It's also important to note that these positive results were attained on patients with more large and complex aneurysms."

MircoVention estimates that 50,000 patients are treated for cerebral aneurysms in the US every year, with a further 100,000 across the globe either undergoing surgery or endovascular treatment.

Source:



Study Demonstrates HydroCoil Embolization System's Superior Safety and Efficacy in Treating Cerebral Aneurysms (03/08/10)

© Adfero Ltd